Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004 Jun;125(5):613-20 PMID: 15147377

Pubmed ID



The European Group for Blood and Marrow Transplantation (EBMT) devised a scoring system to predict survival after allogeneic haematopoietic stem cell transplantation (HSCT) for chronic myeloid leukaemia (CML). The present International Bone Marrow Transplant Registry study of 3211 patients tested the EBMT Risk Score in a independent population, investigated the value of adding other variables, evaluated a new risk score specifically for chronic phase and compared the allograft risk scores with risk scores established by Sokal in 1984 and Hasford in 1998 for survival with non-transplant treatments. The primary outcome was 5-year survival after HSCT; survival curves, regression models and measurements of explained variation were used to compare scores. Using the EBMT scoring system, survival in the independent dataset was almost identical to those in the original EBMT publication, thus validating the EBMT Risk Score. Adding one extra variable, performance status, or designing a score specifically for early chronic phase by using the original five variables with different breakpoints gave results only slightly better than the original EBMT Score. Sokal and Hasford Scores did not predict survival after HSCT. We concluded that the EBMT Risk Score does not currently require modification.

Author List

Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA, Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry


Mary M. Horowitz MD, MS Center Director, Professor in the Medicine department at Medical College of Wisconsin


2-s2.0-2942511357   75 Citations

MESH terms used to index this publication - Major topics in bold

Child, Preschool
Hematopoietic Stem Cell Transplantation
Infant, Newborn
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Middle Aged
Proportional Hazards Models
Risk Assessment
Survival Analysis
Transplantation, Homologous
jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70